Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
66.76
Dollar change
+0.60
Percentage change
0.91
%
IndexNDX, S&P 500 P/E14.82 EPS (ttm)4.50 Insider Own0.10% Shs Outstand1.25B Perf Week-1.92%
Market Cap83.25B Forward P/E9.13 EPS next Y7.31 Insider Trans-2.00% Shs Float1.25B Perf Month-9.76%
Income5.66B PEG2.76 EPS next Q-1.54 Inst Own85.82% Short Float1.81% Perf Quarter-23.52%
Sales27.06B P/S3.08 EPS this Y6.06% Inst Trans0.85% Short Ratio3.05 Perf Half Y-16.20%
Book/sh18.33 P/B3.64 EPS next Y2.58% ROA9.04% Short Interest22.57M Perf Year-20.63%
Cash/sh6.70 P/C9.97 EPS next 5Y5.38% ROE25.71% 52W Range65.90 - 87.86 Perf YTD-17.59%
Dividend Est.3.14 (4.71%) P/FCF11.22 EPS past 5Y1.55% ROI12.16% 52W High-24.02% Beta0.23
Dividend TTM3.02 (4.52%) Quick Ratio1.27 Sales past 5Y4.16% Gross Margin77.94% 52W Low1.31% ATR (14)1.02
Dividend Ex-DateMar 14, 2024 Current Ratio1.43 EPS Y/Y TTM23.94% Oper. Margin33.96% RSI (14)28.55 Volatility1.17% 1.35%
Employees18000 Debt/Eq1.12 Sales Y/Y TTM-0.10% Profit Margin20.93% Recom2.32 Target Price85.03
Option/ShortYes / Yes LT Debt/Eq1.04 EPS Q/Q-12.32% Payout66.62% Rel Volume1.44 Prev Close66.16
Sales Surprise0.20% EPS Surprise-2.18% Sales Q/Q-2.75% EarningsApr 25 AMC Avg Volume7.41M Price66.76
SMA20-4.92% SMA50-7.49% SMA200-12.90% Trades Volume10,656,740 Change0.91%
Date Action Analyst Rating Change Price Target Change
Feb-22-24Downgrade Truist Buy → Hold $91 → $82
Nov-09-23Initiated Deutsche Bank Hold $75
Sep-08-23Upgrade BofA Securities Neutral → Buy $88 → $95
Sep-06-23Initiated HSBC Securities Reduce $71
Jul-24-23Reiterated Barclays Equal Weight $81 → $80
May-16-23Upgrade BMO Capital Markets Market Perform → Outperform $90 → $100
Apr-28-23Resumed Piper Sandler Overweight $105
Jan-03-23Downgrade RBC Capital Mkts Outperform → Sector Perform $87
Dec-13-22Resumed BofA Securities Neutral $85
Dec-09-22Downgrade DZ Bank Buy → Hold $90
Apr-19-24 05:50PM
Apr-18-24 06:33PM
06:00PM
01:45PM
10:01AM
02:03AM Loading…
Apr-17-24 02:03AM
Apr-16-24 09:00AM
Apr-15-24 08:00AM
01:06AM
12:22AM
Apr-12-24 06:00PM
Apr-11-24 09:15AM
Apr-10-24 06:09PM
Apr-09-24 06:15PM
02:40PM
07:37AM Loading…
07:37AM
Apr-08-24 04:05PM
Apr-06-24 06:49AM
Apr-05-24 08:30AM
Apr-03-24 09:00AM
Apr-02-24 06:00PM
09:15AM
Mar-28-24 08:30AM
07:00AM
06:45AM
06:45AM
Mar-26-24 09:15AM
05:15AM
Mar-25-24 06:00PM
Mar-22-24 09:18AM
09:00AM Loading…
Mar-20-24 09:00AM
Mar-19-24 06:00PM
09:05AM
Mar-18-24 07:29PM
08:00AM
Mar-17-24 05:20PM
08:50AM
08:15AM
Mar-15-24 06:00AM
Mar-14-24 09:38AM
Mar-13-24 06:00PM
07:03AM
Mar-12-24 08:45AM
Mar-11-24 08:24AM
08:02AM
Mar-10-24 06:35AM
Mar-07-24 05:50PM
11:31AM
07:59AM
07:15AM
Mar-06-24 04:30PM
10:25AM
09:00AM
08:00AM
06:15AM
Mar-05-24 04:35PM
04:30PM
08:45AM
07:00AM
02:56AM
Mar-01-24 05:50PM
Feb-29-24 08:30AM
06:01AM
Feb-28-24 05:15PM
Feb-27-24 10:00AM
Feb-26-24 04:05PM
08:30AM
08:15AM
Feb-24-24 07:04AM
05:52AM
Feb-22-24 09:00AM
Feb-21-24 04:37PM
Feb-20-24 04:05PM
09:25AM
07:00AM
Feb-19-24 01:46PM
Feb-16-24 05:43AM
Feb-15-24 06:37PM
04:13PM
Feb-13-24 09:24AM
08:30AM
Feb-12-24 04:44PM
04:15PM
01:27PM
12:27PM
12:03PM
11:09AM
09:57AM
09:45AM
09:18AM
08:44AM
08:42AM
08:38AM
08:33AM
08:30AM
06:08AM
Feb-10-24 08:30AM
Feb-09-24 11:00AM
Feb-08-24 01:46PM
01:41PM
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GILEAD SCIENCES, INC.10% OwnerApr 02 '24Buy0.76485,250368,7907,345,473Apr 03 06:50 PM
Parsey MerdadChief Medical OfficerApr 01 '24Sale72.962,000145,92096,304Apr 02 06:38 PM
Parsey MerdadChief Medical OfficerFeb 29 '24Sale72.748,230598,62492,706Feb 29 06:35 PM
Parsey MerdadChief Medical OfficerFeb 28 '24Sale73.182,000146,360100,936Feb 29 06:35 PM
GILEAD SCIENCES, INC.10% OwnerFeb 12 '24Buy22.00910,00020,020,0004,126,119Feb 13 05:48 PM
GILEAD SCIENCES, INC.10% OwnerJan 29 '24Buy21.0015,238,095319,999,99530,061,124Jan 31 05:00 PM
Dickinson Andrew DChief Financial OfficerJan 16 '24Sale85.785,000428,900101,534Jan 17 06:01 PM
Mercier JohannaChief Commercial OfficerJan 09 '24Sale85.238,242702,46682,729Jan 10 03:58 PM
Dickinson Andrew DChief Financial OfficerOct 17 '23Sale80.005,000400,017104,003Oct 18 04:31 PM
Parsey MerdadChief Medical OfficerSep 12 '23Sale76.991,501115,56270,130Sep 13 06:50 PM
Dickinson Andrew DChief Financial OfficerJul 20 '23Sale80.005,000400,000107,587Jul 21 05:30 PM
GILEAD SCIENCES, INC.10% OwnerJun 28 '23Buy19.261,010,00019,452,60014,823,029Jun 30 03:12 PM
GILEAD SCIENCES, INC.10% OwnerJun 27 '23Buy3.752,930,87010,990,76216,635,286Jun 28 05:17 PM
Parsey MerdadChief Medical OfficerJun 13 '23Sale76.901,485114,19729,402Jun 14 05:48 PM